COMMUNIQUÉS West-GlobeNewswire

QHSLab, Inc. Announces Preliminary Unaudited First Quarter Revenue Results
26/04/2024
WEST PALM BEACH, FL, April 26, 2024 (GLOBE NEWSWIRE) -- QHSLab, Inc. ("the Company") (OTCQB: USAQ), a leader in digital health and point-of-care technologies designed to empower clinicians with proactive, value-based [...]
Exagen Inc. Announces Changes to the Board of Directors
26/04/2024
CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott [...]
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
26/04/2024
— If approved in the European Union, fruquintinib will be the first novel targeted therapy for metastatic colorectal cancer regardless of biomarker status in over a decade — — Positive opinion based on results from [...]
Nova Leap Health Corp. Announces Execution of Definitive Agreement
26/04/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, April 26, 2024 (GLOBE NEWSWIRE) -- NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a [...]
Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management
26/04/2024
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX [...]
Neurosurgery Customer from Germany Orders Nexstim NBS System 5
26/04/2024
Press release, Helsinki, 26 April 2024 at 3 PM (EEST) Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an [...]
Smart for Life Announces Availability of a White Paper on the Nutraceuticals Industry
26/04/2024
White Paper Details Recent Trends and Provides Current Industry Data and Analysis on the Growing Nutraceutical Industry MIAMI, April 26, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL) (“Smart for Life” or [...]
Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024
26/04/2024
SAN DIEGO, April 26, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to [...]
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
26/04/2024
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting IRVINE, Calif., April 26, 2024 (GLOBE [...]
Johnson & Johnson receives positive CHMP opinion for RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
26/04/2024
This positive CHMP opinion establishes amivantamab as a new option, and the first fully-human EGFR-MET bispecific antibody, in the first-line treatment of EGFR exon 20 insertion-mutated NSCLC The recommendation is [...]
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
26/04/2024
Decision by EMA follows recent judgment by the Court of Justice of the European Union regarding the organization of EMA’s expert groups Apellis anticipates a CHMP opinion no later than July 2024 WALTHAM, Mass., April 26 [...]
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
26/04/2024
The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ET NEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today [...]
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
26/04/2024
PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results [...]
Interactive Strength Inc. (Nasdaq: TRNR) Strengthens Balance Sheet by Partially Converting Senior Loan to Equity and Extending the Maturity
26/04/2024
Reduced the Liability of the Senior Loan by Converting $3.0 Million to Equity Extended the Maturity of the Remaining Balance to December 2024 AUSTIN, TX, April 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Interactive [...]
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
26/04/2024
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and [...]
Novo Nordisk A/S – Total number of voting rights and share capital in Novo Nordisk A/S as of 26 April 2024
26/04/2024
Bagsværd, Denmark, 26 April 2024 – In accordance with Section 32 of the Danish Capital Markets Act, Novo Nordisk A/S is required to publish the total number of voting rights and the size of the share capital in Novo [...]
The Ensign Group Schedules First Quarter Earnings Call for Thursday, May 2, 2024
26/04/2024
SAN JUAN CAPISTRANO, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]
Composition of the Nomination Committee of Orion Corporation
26/04/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 26 APRIL 2024 at 11.15 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]
Medigene AG reports Financial Results and Business Update for Q1 2024
26/04/2024
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid [...]

Pages